PHVS Pharvaris N.V.
USHealthcareAs of 2026-07-10 16:00
Why PHVS matters now
Pharvaris N.V. (PHVS) is a US stock in Healthcare. The latest InvestLog snapshot shows $35.07 with -2.47% on the session and $2.45B in market capitalization; recent performance reads 1-month +13.30% and YTD +18.20%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-39.8M, and EPS of $-0.61. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -7.4%.
The latest indexable market news headline is "Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $52.00; recent insider activity includes Modig Berndt filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
7.90
P/S
0.00
EV/EBITDA
-10.50
DCF Value
$5.70
FCF Yield
-7.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-67.4%
ROA
-65.1%
ROIC
-72.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-39.8M | $-0.61 |
| Q4 2025 | $0.00 | $-46.7M | $-0.79 |
| FY 2025 | $0.00 | $-175.7M | $-2.97 |
| Q3 2025 | $0.00 | $-37.1M | $-0.60 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$56.00
Target (Median)
$52.00
Target Range
$42.00 - $74.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
NL
Exchange
—
Beta
-2.33
Pharvaris N.V. is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and bringing to market treatments for uncommon diseases. Its primary pipeline asset, PHA121, is a small molecule bradykinin B2-receptor antagonist currently undergoing Phase II clinical trials for hereditary angioedema (HAE). Additionally, the company is advancing PHVS416, a swift-acting, on-demand soft capsule designed to alleviate acute HAE attacks, which is also in Phase 2 development. A third candidate, PHVS719, an extended-release prophylactic tablet aimed at preventing HAE episodes, is progressing through Phase 1 trials. Established in 2015 and headquartered in Leiden, the Netherlands, Pharvaris operates across the Netherlands, Switzerland, and the United States.